ArticleAntiviral research2009
Targeted delivery of anti-coxsackievirus siRNAs using ligand-conjugated packaging RNAs.
Article in Antiviral research, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 43 citations in OpenAlex.
- Chemically Synthesized, Self-Assembling Small Interfering RNA-Prohead RNA Molecules Trigger Dicer-Independent Gene Silencing.Chemistry (Weinheim an der Bergstrasse, Germany) · 2022Article
- Innovative developments and emerging technologies in RNA therapeutics.RNA biology · 2022Article
- Rational design for controlled release of Dicer-substrate siRNA harbored in phi29 pRNA-based nanoparticles.Molecular therapy. Nucleic acids · 2021Article
- "Clicking" Gene Therapeutics: A Successful Union of Chemistry and Biomedicine for New Solutions.Molecular pharmaceutics · 2018Review
- RNA as a stable polymer to build controllable and defined nanostructures for material and biomedical applications.Nano today · 2015Article
- Non-viral nanocarriers for siRNA delivery in breast cancer.Journal of controlled release : official journal of the Controlled Release Society · 2014Review
- Fabrication of pRNA nanoparticles to deliver therapeutic RNAs and bioactive compounds into tumor cells.Nature protocols · 2013Article
- Targeted delivery of siRNA into breast cancer cells via phage fusion proteins.Molecular pharmaceutics · 2013Article
- Article
- Uniqueness, advantages, challenges, solutions, and perspectives in therapeutics applying RNA nanotechnology.Nucleic acid therapeutics · 2012Review
- Progress in targeted delivery of siRNA to combat Coxsackievirus.Protein & cell · 2011Article
- Pharmacological and biological antiviral therapeutics for cardiac coxsackievirus infections.Molecules (Basel, Switzerland) · 2011Review
- Assembly of therapeutic pRNA-siRNA nanoparticles using bipartite approach.Molecular therapy : the journal of the American Society of Gene Therapy · 2011Article
- Optimized method for the synthesis and purification of adenosine--folic acid conjugates for use as transcription initiators in the preparation of modified RNA.Methods (San Diego, Calif.) · 2011Article
- Assembly of multifunctional phi29 pRNA nanoparticles for specific delivery of siRNA and other therapeutics to targeted cells.Methods (San Diego, Calif.) · 2011Review
- Different sequences show similar quaternary interaction stabilities in prohead viral RNA self-assembly.The Journal of biological chemistry · 2011Article
- Engineering cooperative tecto-RNA complexes having programmable stoichiometries.Nucleic acids research · 2011Article
- Fabrication of stable and RNase-resistant RNA nanoparticles active in gearing the nanomotors for viral DNA packaging.ACS nano · 2011Article
- Targeted delivery of mutant tolerant anti-coxsackievirus artificial microRNAs using folate conjugated bacteriophage Phi29 pRNA.PloS one · 2011Article
- The emerging field of RNA nanotechnology.Nature nanotechnology · 2010Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 2 countries.
Funding
Abstract
Coxsackievirus B3 (CVB3) is a common pathogen of myocarditis. We previously synthesized a siRNA targeting the CVB3 protease 2A (siRNA/2A) gene and achieved reduction of CVB3 replication by 92% in vitro. However, like other drugs under development, CVB3 siRNA faces a major challenge of targeted delivery. In this study, we investigated a novel approach to deliver CVB3 siRNAs to a specific cell population (e.g. HeLa cells containing folate receptor) using receptor ligand (folate)-linked packaging RNA (pRNA) from bacterial phage phi29. pRNA monomers can spontaneously form dimers and multimers under optimal conditions by base-pairing between their stem loops. By covalently linking a fluorescence-tag to folate, we delivered the conjugate specifically to HeLa cells without the need of transfection. We further demonstrated that pRNA covalently conjugated to siRNA/2A achieved an equivalent antiviral effect to that of the siRNA/2A alone. Finally, the drug targeted delivery was further evaluated by using pRNA monomers or dimers, which carried both the siRNA/2A and folate ligand and demonstrated that both of them strongly inhibited CVB3 replication. These data indicate that pRNA as a siRNA carrier can specifically deliver the drug to target cells via its ligand and specific receptor interaction and inhibit virus replication effectively.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.